Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study.

CONCLUSION: We observed that bortezomib-based induction is well tolerated in patients with and without cardiac involvement and suggest that this approach be studied in prospective multi-institutional trials.
PMID: 24650974 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - February 16, 2014 Category: Cancer & Oncology Authors: Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT Tags: Clin Lymphoma Myeloma Leuk Source Type: research